Clinical trials
ER+ Breast Cancer clinical trials
Below are recruiting er+ breast cancer clinical trials, each written for real people, not researchers. We’re tracking 558 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06640881RecruitingPhase 2
Repeat breast-conserving surgery with partial reirradiation
This trial tests a new approach for women whose breast cancer has returned in the same breast after earlier surgery and radiation. Instead of removing the whole breast, doctors will remove only the tumor again and give a small, focused dose of radiation before surgery, aiming to preserve the breast.
AmsterdamAges 50 years+ - NCT05056857Recruiting
Study immune-web changes in ER+ breast cancer on tamoxifen
This trial studies how the immune system forms “neutrophil extracellular traps” (immune web material) in people with ER-positive breast cancer who take tamoxifen. It aims to understand whether tamoxifen changes this immune activity over time, which may help explain how it works.
Houston, TexasAges 18 years+ - NCT05768932RecruitingPhase 1
Study drug for advanced cancers or relapsed AML
This Phase 1 trial tests BAL0891, a new study treatment, in people with advanced solid tumors that have run out of treatment options, or in relapsed/refractory acute myeloid leukemia (AML). The goal is to find a safe dose and see how well it may work in these hard-to-treat cancers.
New Haven, ConnecticutAges 18 years+ - NCT06008275RecruitingEarly Phase 1
Neratinib and ruxolitinib for metastatic triple-negative breast cancer
This early-phase trial tests a combination of two targeted drugs, neratinib and ruxolitinib, for people with metastatic triple-negative breast cancer who have already had standard chemotherapy. The goal is to see if the combination is safe and effective.
Dallas, TexasAges 18 years+ - NCT06086704RecruitingPhase 2
PET/MRI scan for PR-positive breast cancer before surgery
This trial tests a new PET/MRI scan (using a special tracer called 18F-FFNP) to see how it images progesterone-receptor-positive breast cancer before surgery. You would get the scan and then have your planned surgery.
Madison, WisconsinAges 18 years+ - NCT06365788RecruitingPhase 2
Bicalutamide and Abemaciclib for AR-positive Triple-negative Breast Cancer
This trial tests a combination of two oral drugs—bicalutamide and abemaciclib—for people with a specific type of advanced triple-negative breast cancer that grows in response to androgen hormones (AR-positive). The goal is to see if this treatment can shrink tumors or slow disease progression.
AntwerpAges 18 years+ - NCT04025164Recruiting
Shorter vs standard breast radiation after lumpectomy
This study compares a shorter course of radiation to a standard longer course after breast-conserving surgery (lumpectomy). It’s meant to see which schedule works just as well while focusing on safety and cancer control.
Guiyang, GuizhouAges 18–70 - NCT05978648RecruitingPhase 2
Trilaciclib for early-stage HR-negative breast cancer after surgery
This trial tests if adding trilaciclib to standard chemotherapy after surgery can help people with hormone receptor-negative breast cancer. It aims to reduce side effects and improve treatment outcomes.
Guangzhou, GangdongAges 18 years+ - NCT05307705RecruitingPhase 1
Testing LOXO-783 for PIK3CA-mutated cancers
This trial tests an experimental drug (LOXO-783) for people with advanced breast cancer or other solid tumors that have a specific change in the PIK3CA gene. The goal is to see if the drug can shrink or slow the growth of the cancer.
Scottsdale, ArizonaAges 18 years+ - NCT04428528Recruiting
Ultrasound-like pictures that track breast tumors during chemotherapy
This study uses a special light-based imaging scan to learn more about breast masses and how tumors may respond to chemotherapy before surgery. The scan is meant to help doctors better characterize tumors and potentially track treatment response.
Toronto, OntarioAges Any age - NCT07297667RecruitingPhase 1
CAR T-cell therapy for GPNMB-positive solid tumours
This trial tests a new immune cell therapy (CAR T-cells) that targets a protein called GPNMB found on some tumour types. It's for people with advanced alveolar soft part sarcoma, certain kidney cancers, or triple-negative breast cancer that hasn't responded to standard treatments.
Calgary, AlbertaAges 15 years+ - NCT06598046RecruitingPhase 2
Utidelone and Capecitabine for triple-negative breast cancer brain metastases
This trial tests a combination of two chemotherapy drugs (Utidelone and Capecitabine) for people with triple-negative breast cancer that has spread to the brain. The goal is to see if the combination can shrink or control the brain tumors.
Zhengzhou, HenanAges 18 years+ - NCT06184750RecruitingPhase 2
Finding the best tamoxifen dose to lower breast cancer risk
This trial tests different doses of tamoxifen to find the best one for lowering breast cancer risk in premenopausal women. It aims to see if a lower dose works as well as the standard dose with fewer side effects.
Tucson, ArizonaAges 18–55 - NCT06081244RecruitingPhase 3
Testing sacituzumab govitecan with or without pembrolizumab for early triple-negative breast cancer
This trial tests a two-drug combination (sacituzumab govitecan and pembrolizumab) versus sacituzumab govitecan alone before surgery for low-risk, triple-negative breast cancer that hasn't spread. The goal is to see which approach works better at shrinking tumors.
Baden-Baden, Baden-WurttembergAges 18 years+ - NCT07287917RecruitingPhase 1/Phase 2
Testing a new drug combo for advanced breast cancer or melanoma
This trial tests a new combination of drugs (AMXT 1501, DFMO, and standard therapies) for people with advanced solid tumors, specifically breast cancer (ER+ HER2-) or melanoma that has progressed after other treatments. The goal is to see if this combination can help shrink tumors or slow their growth.
Tucson, ArizonaAges 18 years+ - NCT06028022RecruitingPhase 2
Reishi mushroom for fatigue and joint/muscle pain in breast cancer
This trial tests whether a reishi mushroom extract can help reduce fatigue and joint or muscle pain in people with breast cancer who are taking aromatase inhibitors. If you have these symptoms, you may be able to join.
Albert Lea, MinnesotaAges 18 years+ - NCT06544577Recruiting
Elacestrant for advanced ER+/HER2- breast cancer with ESR1 mutation
This trial tests an oral drug called elacestrant in women whose ER+/HER2- breast cancer has worsened after at least one hormone therapy. It is for those with a specific genetic change (ESR1 mutation) and advanced or metastatic disease.
Qionghai, HainanAges 18 years+ - NCT05973864RecruitingPhase 2
Capecitabine plus pembrolizumab after TNBC surgery and chemo
This Phase 2 trial studies whether adding capecitabine to pembrolizumab after surgery can lower the risk of cancer coming back in people with triple-negative breast cancer that didn’t fully respond to earlier treatment. It’s meant for patients whose tumor was removed but still showed remaining cancer after chemo-immunotherapy.
AmiensAges 18 years+ - NCT06992336RecruitingPhase 2
Circulating tumor DNA guided extra treatment for early triple-negative breast cancer
This trial tests whether using a blood test to detect leftover cancer DNA after initial treatment can help doctors decide if extra therapy is needed for people with early triple-negative breast cancer. It aims to improve outcomes for those with remaining disease after neoadjuvant therapy.
Guangzhou, GuangodngAges 18–70 - NCT07467330RecruitingPhase 3
Breast cancer trial: Adding capecitabine to standard treatment
This trial tests if adding a chemotherapy drug called capecitabine to the combination of dalpiciclib and hormone therapy works better than dalpiciclib and hormone therapy alone for advanced breast cancer that is hormone receptor-positive and HER2-negative. It is for people who have not had these treatments before.
Fuzhou, FujianAges 18 years+ - NCT06382818Recruiting
Personalized breast radiation based on risk and side effects
This trial tests whether radiation therapy can be personalized based on your risk of the cancer coming back and your risk of side effects from radiation. Depending on those factors, you may receive a tailored radiation plan that could be more or less intense.
MontpellierAges 18 years+ - NCT05451784RecruitingPhase 1/Phase 2
PD-1 TIL therapy for advanced triple-negative breast cancer
This study tests an immune-cell treatment made from your tumor tissue. It aims to help people with advanced or metastatic triple-negative breast cancer by collecting PD-1–positive immune cells and giving them back after treatment.
BarcelonaAges 18 years+ - NCT06926868RecruitingPhase 2/Phase 3
Study of a new drug versus chemotherapy for advanced triple-negative breast cancer
This trial tests a new investigational drug called izalontamab brengitecan against standard chemotherapy for people with advanced triple-negative breast cancer who cannot receive immunotherapy. The goal is to see if the new drug works better at shrinking or slowing the cancer.
Hot Springs, ArkansasAges 18 years+ - NCT06245889RecruitingPhase 2
PET-Guided Therapy for Triple-Negative Breast Cancer
This trial tests whether a special PET scan can help guide the best combination of chemotherapy and immunotherapy before surgery for patients with triple-negative breast cancer. It aims to personalize treatment and improve outcomes.
Baltimore, MarylandAges 18 years+
Hear when a new ER+ Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for er+ breast cancer?
- Yes. Clin2 currently lists 558 recruiting er+ breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a er+ breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a er+ breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.